Potential role of endothelin-1 in pulmonary fibrosis: From the bench to the clinic

American Journal of Respiratory Cell and Molecular Biology

Volumn 42, Issue 1, 2010, Pages 16-20

  Ross, Bryan ^a   D'Orléans Juste, Pedro ^b   Giaid, Adel ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b UNIVERSITÉ DE SHERBROOKE   (Canada)

Author keywords

Endothelin receptor antagonist; Extracellular matrix; Idiopathic pulmonary fibrosis; Lungs, human; Myofibroblast

Indexed keywords

2 (4 BIPHENYLYL) 1 (1H TETRAZOL 5 YL)ETHYLAMINOMETHYLPHOSPHONIC ACID; BOSENTAN; CONNECTIVE TISSUE GROWTH FACTOR; ENDOTHELIN 1; ENDOTHELIN CONVERTING ENZYME; ENDOTHELIN CONVERTING ENZYME INHIBITOR; ENDOTHELIN RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; INTERLEUKIN 1; MACITENTAN; N [1 BENZYL 2,3 DIOXO 6 (2 PYRIDYLOXY)HEXYL] 2 (5 FORMYLAMINO 1,6 DIHYDRO 6 OXO 2 PHENYL 1 PYRIMIDINYL)ACETAMIDE; PLACEBO; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

CELL DIFFERENTIATION; CELL FUNCTION; CELL TRANSFORMATION; CHRONIC INFLAMMATION; CLINICAL TRIAL; DRUG SAFETY; DRUG TOLERABILITY; ENDOTHELIUM CELL; EPITHELIUM CELL; FIBROSING ALVEOLITIS; HUMAN; LUNG DISEASE; LUNG FIBROBLAST; LUNG FIBROSIS; MEDIATOR; MESENCHYME CELL; MYOFIBROBLAST; NONHUMAN; PROTEIN BINDING; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION; WOUND HEALING; ANIMAL; APOPTOSIS; BIOLOGICAL MODEL; DRUG ANTAGONISM; EXTRACELLULAR MATRIX; FIBROBLAST; LUNG; METABOLISM; MOUSE; MUSCLE CONTRACTION; PHYSIOLOGY; TIME;

ANIMALS; APOPTOSIS; CELL DIFFERENTIATION; ENDOTHELIN-1; EXTRACELLULAR MATRIX; FIBROBLASTS; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; LUNG; MICE; MODELS, BIOLOGICAL; MUSCLE CONTRACTION; RECEPTORS, ENDOTHELIN; TIME FACTORS; WOUND HEALING;

EID: 73949159217     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/rcmb.2009-0175TR     Document Type: Review

References (35)

1. Clozel M, Salloukh H. Role of endothelin in fibrosis and anti-fibrotic potential of bosentan. Ann Med 2005;37:2-12.
2. Abraham D. Role of endothelin in lung fibrosis. Eur Respir Rev 2008;17:145-150.
3. Uguccioni M, Pulsatelli L, Grigolo B, Facchini A, Fasano L, Cinti C, Fabbri M, Gasbarrini G, Meliconi R. Endothelin-1 in idiopathic pulmonary fibrosis. J Clin Pathol 1995;48:330-334.
4. Reichenberger F, Schauer J, Kellner K, Sack U, Stiehl P, Winkler J. Different expression of endothelin in the bronchoalveolar lavage in patients with pulmonary diseases. Lung 2001;179:163-174.
5. Shahar I, Fireman E, Topilsky M, Grief J, Schwarz Y, Kivity S, Ben-Efraim S, Spirer Z. Effect of endothelin-1 on a-smooth muscle actin expression and on alveolar fibroblasts proliferation in interstitial lung diseases. Int J Immunopharmacol 1999;21:759-775.
6. Park SH, Saleh D, Giaid A, Michel RP. Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist. Am J Respir Crit Care Med 1997;156:600-608.
7. Mutsaers SE, Foster ML, Chambers RC, Laurent GJ, McAnulty RJ. Increased endothelin-1 and its localization during the development of bleomycin-induced pulmonary fibrosis in rats. Am J Respir Cell Mol Biol 1998;18:611-619.
8. Wendel M, Petzold A, Koslowski R, Kasper M, Augstein A, Knels L, Bleyl JU, Koch T. Localization of endothelin receptors in bleomycin-induced pulmonary fibrosis in the rat. Histochem Cell Biol 2004;122:507-517.
9. Hocher B, Schwarz A, Fagan KA, Thöne-Reineke C, El-Hag K, Kusserow H, Elitok S, Bauer C, Neumayer HH, Rodman DM, et al. Pulmonary fibrosis and chronic lung inflammation in ET-1 transgenic mice. Am J Respir Cell Mol Biol 2000;23:19-26.
10. Fagan KA, McMurtry IF, Rodman DM. Role of endothelin-1 in lung disease. Respir Res 2001;2:90-101.
11. Leuchte HH, Meis T, El-Nounou M, Michalek J, Behr J. Inhalation of endothelin receptor blockers in pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2008;294:L772-L777.
12. Giaid A, Michel RP, Stewart DJ, Sheppard M, Hamid Q, Corrin B. Expression of endothelin-1 in lungs of patients with cryptogenic fibrosing alveolitis. Lancet 1993;341:1550-1554.
13. Saleh D, Furukawa K, Tsao MS, Maghazachi A, Corrin B, Yanagisawa M, Barnes PJ, Giaid A. Elevated expression of endothelin-1 and endothelin- converting enzyme-1 in idiopathic pulmonary fibrosis: possible involvement of proinflammatory cytokines. Am J Respir Cell Mol Biol 1997;16:187-193.
14. Laurent GJ, McAnulty RJ, Hill M, Chambers R. Escape from the matrix: multiple mechanisms for fibroblast activation in pulmonary fibrosis. Proc Am Thorac Soc 2008;5:311-315.
15. Gross TJ, Hunninghake GW. Idiopathic pulmonary fibrosis. N Engl J Med 2001;345:517-525.
16. Simard E, Jin D, Takai S, Miyazaki M, Brochu I, D'Orléans-Juste P. Chymase-dependent conversion of big endothelin-1 in the mouse in vivo. J Pharmacol Exp Ther 2009;328:540-548.
17. Giaid A, Polak JM, Gaitonde V, Hamid QA, Moscoso G, Legon S, Uwanogho D, Roncalli M, Shinmi O, Sawamura T, et al. Distribution of endothelin-like immunoreactivity and mRNA in the developing and adult human lung. Am J Respir Cell Mol Biol 1991;4:50-58.
18. Finses F, Skjonsberg OH, Tonnessen T, Naess O, Lyberg T, Christensen G. Endothelin production and effects of endothelin antagonism during experimental airway inflammation. Am J Respir Crit Care Med 1997;155:1404-1412.
19. Shi-Wen X, Kennedy L, Renzoni EA, Bou-Gharios G, du Bois RM, Black CM, Denton CP, Abraham DJ, Leask A. Endothelin is a downstream mediator of profibrotic responses to transforming growth factor β in human lung fibroblasts. Arthritis Rheum 2007;56:4189-4194.
20. McAnulty RJ. Fibroblasts and myofibroblasts: their source, function and role in disease. Int J Biochem Cell Biol 2007;39:666-671.
21. Edwards ST, Cruz AC, Donnelly S, Dazin PF, Schulman ES, Jones KD, Wolters PJ, Hoopes C, Dolganov GM, Fang KC. c-Kit immunophenotyping and metalloproteinase expression profiles of mast cells in interstitial lung diseases. J Pathol 2005;206:279-290.
22. Seibold JR, Black CM, Denton CP, Furst DE, Guillevin L, Rubin LJ, Wells A, Charef P, Roux S, Chadha-Boreham H. Bosentan versus placebo in interstitial lung disease secondary to systemic sclerosis (SSc): the BUILD-2 study. ATS 2006;A243.
23. Willis BC, Borok Z. TGF-β-induced EMT: mechanisms and implications for fibrotic lung disease. Am J Physiol Lung Cell Mol Physiol 2007;293:L525-L534.
24. Kim KK, Chapman HA. Endothelin-1 as initiator of epithelial-mesenchymal transition. Am J Respir Cell Mol Biol 2007;37:1-2.
25. Jain R, Shaul PW, Borok Z, Willis BC. Endothelin-1 induces alveolar epithelial-mesenchymal transition through endothelin type A receptor-mediated production of TGF-β1. Am J Respir Cell Mol Biol 2007;37:38-47.
26. Shi-Wen X, Chen Y, Denton CP, Eastwood M, Renzoni EA, Bou-Gharios G, Pearson JD, Dashwood M, du Bois RM, Black CM, et al. Endothelin-1 promotes myofibroblast induction through the ETA receptor via a Rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts. Mol Biol Cell 2004;15:2707-2719.
27. Desmoulière A, Darby IA, Gabbiani G. Normal and pathologic soft tissue remodeling: role of the myofibroblast, with special emphasis on liver and kidney fibrosis. Lab Invest 2003;83:1689-1707.
28. Kim R, Mayer K. Therapies for interstitial lung disease: past, present and future. Ther Adv Respir Dis 2008;2:319-338.
29. Kavanagh M, Battistini B, Kluth D, Jean S, Fournier L, Jeng AY, Major D, Cloutier R. Effect of CGS 26303, an endothelin-converting enzyme-neutral endopeptidase inhibitor, on nitrofen-induced congenital diaphragmatic hernia in the rat. J Pediatr Surg 2000;35:780-784.
30. Eckman EA, Watson M, Marlow L, Sambamurti K, Eckman CB. Alzheimer's disease beta-amyloid peptide is increased in mice deficient in endothelin-converting enzyme. J Biol Chem 2003;278:2081-2084.
31. Sakaguchi M, Takai S, Jin D, Okamoto Y, Muramatsu M, Kim S, Miyazaki M. A specific chymase inhibitor, NK3201, suppresses bleomycin-induced pulmonary fibrosis in hamsters. Eur J Pharmacol 2004;493:173-176.
32. Iglarz M, Binkert C, Morrison K, Fischli W, Gatfield J, Treiber A, Weller T, Bolli MH, Boss C, Buchmann S, et al. Pharmacology of Macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther 2008;327:736-745.
33. Günther A, Enke B, Markart P, Hammerl P, Morr H, Behr J, Stähler G, Seeger W, Grimminger F, Leconte I, et al. Safety and tolerability of bosentan in idiopathic pulmonary fibrosis: an open label study. Eur Respir J 2007;29:713-719.
34. King TE, Behr J, Brown KK, du Bois RM, Lancaster L, de Andrade JA, Stähler G, Leconte I, Roux S, Raghu G. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008;177:75-81.
35. Hachulla E, Launay D, Humbert M. Bosentan for the treatment of scleroderma. Future Rheumatol 2006;1:549-562.